Cross-Protection in PRRSV: Mechanisms, Limitations, and Implications for Vaccine Design
Pathogens · 24.03.2026 · 15 (4) · 345
DOI: 10.3390/pathogens15040345 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathogens, online erschienen am 24.03.2026. Verfasst von Sergei A Raev und 5 weiteren Autor:innen. Beteiligte Einrichtung: Center on Biologics Development and Evaluation, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA. Hauptthemen laut MEDLINE: Porcine respiratory and reproductive syndrome virus, Porcine Reproductive and Respiratory Syndrome, Viral Vaccines, Cross Protection. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 162 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Agriculture, Agricultural Research Service, U.S. Department of Agriculture’s National Institute of Food and Agriculture.
Abstract (Originalsprache)
Porcine reproductive and respiratory syndrome (PRRS) remains one of the most economically devastating diseases in global swine production. The causative agent, PRRS virus (PRRSV), comprises two genetically distinct species—PRRSV-1 and PRRSV-2—that differ substantially in antigenic composition and immune recognition. Despite widespread use of modified live vaccines (MLVs), protection against heterologous and cross-species strains remains inconsistent and difficult to predict. This review synthesizes current knowledge of homologous, heterologous, and cross-species protection, with emphasis on humoral and cellular immune responses and the viral determinants that constrain breadth of immunity. Neutralizing antibodies can confer near-sterilizing homologous protection under controlled conditions; however, their delayed induction and narrow specificity limit efficacy against heterologous strains. T-cell-mediated responses are generally broader but remain highly strain- and context-dependent. Structural features of PRRSV envelope glycoproteins, including glycan shielding and immunodominant decoy epitopes, further restrict antibody-mediated cross-protection while providing targets for rational vaccine design. We also examine potential drawbacks of preexisting immunity, including antigenic mismatch and non-neutralizing antibody-dominated responses that may contribute to suboptimal outcomes following heterologous exposure. Collectively, these findings highlight the multifactorial nature of PRRSV protection and the need for next-generation vaccines capable of inducing broader and more durable immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center on Biologics Development and Evaluation, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.
- Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA.
ORCID-Profile: Sergei A Raev, Rachel Madera, Lihua Wang, Jishu Shi
Förderung
- United States Department of Agriculture
- Agricultural Research Service
- U.S. Department of Agriculture’s National Institute of Food and Agriculture
- National Bio and Agro-Defense Facility Transition Fund
- USDA National Institute of Food and Agriculture
- USDA ARS Non-Assistance Cooperative Agreements
- USDA NIFA Subaward
Zitieren
APA
Raev, S. A., Cai, L., Muro, N., Madera, R., Wang, L., & Shi, J. (2026). Cross-Protection in PRRSV: Mechanisms, Limitations, and Implications for Vaccine Design. Pathogens, 15(4), 345. https://doi.org/10.3390/pathogens15040345
Vancouver
Raev SA, Cai L, Muro N, Madera R, Wang L, Shi J. Cross-Protection in PRRSV: Mechanisms, Limitations, and Implications for Vaccine Design. Pathogens. 2026;15(4):345. doi:10.3390/pathogens15040345
BibTeX
@article{Raev2026,
author = {Raev, Sergei A and Cai, Limeng and Muro, Nina and Madera, Rachel and Wang, Lihua and Shi, Jishu},
title = {Cross-Protection in PRRSV: Mechanisms, Limitations, and Implications for Vaccine Design},
journal = {Pathogens},
year = {2026},
volume = {15},
number = {4},
pages = {345},
doi = {10.3390/pathogens15040345}
}
EUVIMED